The company also signed a licensing agreement on the same product for all countries except Japan with Teikoku Seiyaku’s US subsidiary, Teikoku Pharma USA.
Under the terms of the agreement, Teikoku USA will develop the product for the US market and Eisai will have exclusive marketing rights. In Japan, Eisai has option rights concerning development and marketing. In other territories, Eisai has secured exclusive development and marketing rights.
In addition, Eisai obtained an option right to enter into an exclusive license agreement to develop and commercialize the second generation product in all countries except Japan from Teikoku USA and Teikoku Seiyaku.
Eisai said that it is working to enhance patient value by adding new indications and formulations of donepezil hydrochloride (Aricept). With these agreements, Eisai will aim to provide a new formulation option and continue to make further contributions to addressing the diversified needs of the people living with Alzheimer’s disease, and to improving their benefits.
Eisai a research-based human health care company focuses on discovering, developing and marketing products worldwide.
Teikoku Seiyaku is focused on pain relief and development of new types of medicated patches and plasters.